seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from Türkiye
seen from Türkiye
seen from United States
seen from Greece
seen from Türkiye
seen from United States
seen from China
seen from United Kingdom
seen from Türkiye
seen from Canada
seen from Canada
seen from Spain
seen from United States
seen from United States
seen from Ecuador
Linagliptin 5mg
Linagliptin 5 mg is an oral antidiabetic medication used primarily for the treatment of Type 2 Diabetes Mellitus. Linagliptin 5mg belongs to
Linagliptin 5 mg is an oral antidiabetic medication used primarily for the treatment of Type 2 Diabetes Mellitus. Linagliptin 5mg belongs to the class of drugs known as DPP-4 inhibitors (Dipeptidyl Peptidase-4 inhibitors).
Daicel Pharma manufactures high-quality Linagliptin impurities. We also offer custom synthesis of Linagliptin impurities and supply worldwid
Linagliptin Impurity Standards
Linagliptin is a medication used to treat type 2 diabetes mellitus. It belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors. Linagliptin works by increasing the levels of incretin hormones in the body. Incretins are hormones that stimulate the release of insulin after meals, helping to control blood sugar levels.
https://www.simsonpharma.com/promotions/Linagliptin-impurity-standards
Trifluoro Acetyl Amino Linagliptin
CAT. No.L460031
CAS. No.1673546-62-7
Mol. F.C27H27F3N8O3
Mol. Wt.568.55 g/mol
Synonyms: N-[(3R)-1-[7-(2-Butyn-1-yl)-2,3,6,7-tetrahydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-2,6-dioxo-1H-purin-8-yl]-3-piperidinyl]-2,2,2-trifluoroacetamide;N-[(3R)-1-[7-(but-2yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl]piperidin-3-yl]-2,2,2-trifluoro acetamide;3-Trifluoroacetylamino Linagliptin
Know more:- https://www.simsonpharma.com/product/trifluoro-acetyl-amino-linagliptin-14484
the global and regional analysis of Linagliptin in terms of Dosage, Strength, API, application Wise segmentation, market size and market growth (in terms of value and volume) trends including forecasting upto 5 years
Linagliptin Introduction
“Linagliptin” is White to yellow crystalline solid soluble in water. Derivative of quinazoline & purine used as hypoglycemic agent in type II Diabetes mellitus medication. Two pharmacological characteristics that sets Linagliptin apart from other DPP-4 inhibitors is that it has a non-linear pharmacokinetic profile and is not primarily eliminated by the renal system, available in various dosage & combination tablets. Linagliptin is a competitive and reversible dipeptidyl peptidase (DPP)-4 enzyme inhibitor which slows the breakdown of insulinotropic hormone glucagon-like peptide (GLP)-1 for better glycemic control in diabetes patients. GLP and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones that increase the production and release of insulin from pancreatic beta cells and decrease the release of glucagon from pancreatic alpha cells. This results in an overall decrease in glucose production in the liver and increase of insulin in a glucose-dependent manner.
This report represents the global and regional analysis of Linagliptin in terms of Dosage, Strength, API, application Wise segmentation, market size & market growth (in terms of value & volume) trends including forecasting upto 5 years. All the region wise segmentation of buyer supplier is described properly. The report focuses on the top continent Wise (North America, Europe, Japan, China and other regions (India, Southeast Asia, Central & South America, and Middle East & Africa) manufacturer & buyers also.
Linagliptin
Brand Name: Tradjenta
Common Dosage Forms:
Tablets: 5 mg
FDA Indications/Dosages:
As an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus: 5 mg taken once daily.
When used with an insulin secretagogue (sulfonylurea) or with insulin, use a lower dose of the insulin secretagogue or insulin to decrease the risk of hypoglycemia.
Monitor: FBG, HbA1C
Pharmacology/Pharmacokinetics: Linagliptin inhibits the dipeptidyl peptidase-4 (DDP-4) enzyme. DDP-4 is responsible for deactivating the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones are released by the intestine in response to food and are credited with increasing insulin synthesis and release from pancreatic beta cells. GLP-1 also decreases hepatic glucose production by lowering glucagon secretion from pancreatic alpha cells. By inhibiting DDP-4, linagliptin increases insulin and decreases glucagon in response to elevated blood glucose. Inhibition of DDP-4 by sitagliptin lasts for 24 hours. Peak plasma levels are reached in 1.5 hours. Approximately 85% is excreted in the urine as unchanged drug. The terminal half-life after an oral dose is approximately 12 hours.
Drug Interactions: Strong inducers of CYP3A4 or P-gp (rifampin) may decrease effectiveness.
Contraindications/Precautions: Contraindicated in patients with known or suspected hypersensitivity to linagliptin. Increases the risk of acute pancreatitis (upper abdominal pain, nausea and vomiting, fever). Use caution when combining with medications known to cause hypoglycemia. Hypersensitivity reactions have occurred within 3 months of starting therapy. Pregnancy Category B.
Adverse Effects: Adverse effects are uncommon and mild and include nasopharyngitis, diarrhea, and cough. A rare adverse effect seen with other DDP-4 inhibitors is joint pain (arthralgia). Rare but severe cases of hypersensitivity and pancreatitis have been reported.
Patient Consultation:
May be taken without regard to meals.
Closely follow recommended dietary and exercise instructions.
Quarterly HbA1c testing should be performed.
Store in a cool, dry place away from sunlight and children.
If a dose is missed, take it as soon as possible but do not double doses.
Call physician is above side effects are severe or persistent.
Linagliptin - an inhibitor of dipeptidyl peptidase-4 (DPP-4) which prevent the hormone incretin from being degraded thus allowing the pancreas is stimulated to produce more insulin. It can potentially be used for the treatment of type 2 diabetes and may protect vascular health by reducing arterial stiffness.
Obat Kombinasi Baru SGLT2 dan DPP-4 Untuk Diabetes Tipe 2 Diluncurkan di Eropa
Obat Kombinasi Baru SGLT2 dan DPP-4 Untuk Diabetes Tipe 2 Diluncurkan di Eropa
farmasetika.com – Komisi Eropa menyetujui obat Glyxambi® (empagliflozin/linagliptin) dari gabungan perusahaan Boehringer Ingelheim dan Eli Lilly Diabetes Alliance untuk digunakan pada orang dewasa dengan diabetes tipe 2 (T2D) di Uni Eropa (UE).
Tentang Diabetes
Lebih dari 415 juta orang di seluruh dunia mengidap diabetes, 193 juta diantaranya diperkirakan tidak terdiagnosa. Hingga tahun 2040,…
View On WordPress
